Bristol Myers Squibb and bluebird bio submit BLA for Idecabtagene Vicleucel to FDA

This article was originally published here

The submission is based on results from the pivotal Phase 2 KarMMa study. The KarMMa study evaluated the efficacy and safety of ide-cel in heavily pre-treated patients with

The post Bristol Myers Squibb and bluebird bio submit BLA for Idecabtagene Vicleucel to FDA appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply